OLIGOSACCHARIDE SYNTHESIS
It is through their structural complexity that oligosaccharides are able to mediate biospecific information, one example being sialyl-Lewisx tetrasaccharide, a crucial molecule in cell adhesion and trafficking3 5'6 . The mechanism of their synthesis is therefore crucial. At the centre stage of the synthesis of glycoside bonds are the glycosyltransferases whose specificity for their substrates, the donor sugar nucleotides, and their acceptor is precise ('one enzyme-one linkage '7) . The sequential action of glycosyltransferases produces oligosaccharide and glycan structures that reflect the constitution of the multiglycosyltransferase system8 of a given cell type and implies that the targeting mechanism for glycosyltransferases along the secretory pathway is highly ordered9.
The most important organelle involved in glycosylation is the Golgi apparatus (GA) originally described as appareil re'ticulaire interne by Camillo Golgi in 1898 and subsequently confirmed to be a morphological entity by electron microscopyl0. Its number of copies of the oligosaccharides and their precise geometry of presentation17. These factors introduce a high degree of specificity and control.
The finding that glycosylation may vary with disease also leads to the concept that therapeutic manipulation might beneficially alter the properties of glycoproteins18'19. The ability to manipulate and modify sugar structures also provides an important approach in understanding the different functions of oligosaccharides. For instance, control of glycosylation can be influenced by amino sugars such as N-butyldeoxynojirimycin (B-DNJ), which inhibits the processing enzymes a-glucosidases I and II. Treatment of human immunodeficiency virus (HIV) with this compound modifies the N-glycan conformation of the envelope glycoproteins, inhibiting syncytium formation in infected cells and reducing the infectivity of released virus. The binding of virus to CD4 receptors is not affected, but entry (fusion) is greatly altered. The effect is correlated with the amino sugars causing a conformational change in Vl/V2 region of gp 120. Presumably the altered glycosylation prevents interaction with carbohydrate-specific protein folding chaperones (such as calnexin) in the endoplasmic reticulum19.
In contrast to the HIV envelope glycoproteins, which contain about 30 acetylglucosamine-bearing structures. Agalactosyl-IgG is such a structure and when bound by mannose binding protein the result may be complement activation. This is thought to trigger an inflammatory process39. Animal models of arthritis have been developed in which the inflammatory process is triggered by agalactosyl-IgG40.
Galactosyltransferase
Glycosylation homoeostasis within rheumatoid arthritis lymphocytes is thought to be abnormal. In healthy individuals there is a positive feedback mechanism ensuring that galactosyltransferase levels increase as IgG galactose levels decline. In rheumatoid arthritis this does not occur41. Where does this breakdown in enzymatic control arise? Not only is the overall galactosyltransferase activity reduced within lymphocytes, but serum galactosyltransferase isoenzymes vary42.
There are two peaks of enzymatic activity in serum after isoelectric focusing. In rheumatoid arthritis, unlike psoriatic arthritis and other rheumatic diseases, there is a significant acidic shift in the galactosyltransferase activity profile, with a unique peak forming at pH 5 
